Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

Conditions

• Metastatic Hormone-sensitive Prostate Cancer

Interventions

• DRUG: Apalutamide (Erleada™) 60 mg or 240 mg tablets
• DRUG: Docetaxel

Sponsor

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Collaborators

• [object Object]